LMR Partners’s Milestone Pharmaceuticals MIST Stock Holding History

LMR Partners’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-38,495	Closed	-$119K	–	1073
2023 Q3	$119K	Hold	38,495	–	–	﹤0.01%	666
2023 Q2	$110K	Hold	38,495	–	–	﹤0.01%	615
2023 Q1	$152K	Hold	38,495	–	–	﹤0.01%	890
2022 Q4	$152K	Hold	38,495	–	–	﹤0.01%	1015
2022 Q3	$354K	Buy	38,495 +26,763	+228%	+$203K	0.01%	940
2022 Q2	$72K	Buy	+11,732	New	+$72.1K	﹤0.01%	1123

Other funds holding MIST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

LMR Partners's MIST Position: Q4 2023 in Review

LMR Partners sold out of Milestone Pharmaceuticals (MIST) in Q4 2023, closing a stake of 38,495 shares — an estimated $119K sold.

LMR Partners first reported a position in MIST in Q2 2022 and held it in 6 quarters. The position peaked at $354K in Q3 2022. 40 funds tracked by Wall St. Rank hold MIST as of Q4 2023.

LMR Partners reported no remaining Milestone Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
LMR Partners sold 38,495 Milestone Pharmaceuticals shares in Q4 2023, an estimated $119K.
LMR Partners first reported a position in Milestone Pharmaceuticals in Q2 2022 and held it in 6 quarters.
LMR Partners's Milestone Pharmaceuticals position peaked at $354K in Q3 2022.
40 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2023.

Based on LMR Partners's 13F filing for Q4 2023, filed 14 Feb 2024.